Phase II study of new risk classification and high-dose chemotherapy for medulloblastoma

Phase 2

Recruiting

• Conditions: Medulloblastoma; D008527

• Registration Number: JPRN-jRCTs051200021
• Lead Sponsor: Hara Junichi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-05-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 229

Inclusion Criteria

1) Locally diagnosed as medulloblastoma after tumor resection or biopsy
2) Protocol treatment can be started within 6 weeks after surgery
3) Less than 30 years
4) No prior radiation or chemotherapy
5) ECOG Performance Status (PS) is 3 or less

Exclusion Criteria

1) Active double cancer (synchronous double cancer and metachronous double cancer with disease-free period of 5 years or less).
2) Complicated with extracranial metastasis (M4).
3) Complicated heart disease requiring treatment.
4) You are pregnant or nursing.

Study & Design

• Study Type: Interventional
• Study Design: Not specified